1,170
Participants
Start Date
November 30, 2012
Primary Completion Date
February 28, 2013
Study Completion Date
June 30, 2014
Decision aid
Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
SFTG, Paris
University of Paris 5 - Rene Descartes
OTHER
University Paris 7 - Denis Diderot
OTHER